Clinical applications of nucleic acid aptamers in cancer (Review)

Pei,Xiaoyu; Zhang,Jun; Liu,Jie

doi:10.3892/mco.2014.255

Clinical applications of nucleic acid aptamers in cancer (Review)

Authors:
- Xiaoyu Pei
- Jun Zhang
- Jie Liu
View Affiliations

Affiliations: Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: February 10, 2014 https://doi.org/10.3892/mco.2014.255
Pages: 341-348

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nucleic acid aptamers are small single‑stranded DNA or RNA oligonucleotide segments, which bind to their targets with high affinity and specificity via unique three‑dimensional structures. Aptamers are generated by an iterative in vitro selection process, termed as systematic evolution of ligands by exponential enrichment. Owing to their specificity, non‑immunogenicity, non‑toxicity, easily modified chemical structure and wide range of targets, aptamers appear to be ideal candidates for various clinical applications (diagnosis or treatment), such as cell detection, target diagnosis, molecular imaging and drug delivery. several aptamers have entered the clinical pipeline for applications in diseases such as macular degeneration, coronary artery bypass graft surgery and various types of cancer. The aim of this review was to summarize and highlight the clinical applications of aptamers in cancer diagnosis and treatment.

View Figures

View References

1.	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
3.	Rajendran L, Knolker HJ and Simons K: Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov. 9:29–42. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Blagosklonny MV: Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle. 3:1035–1042. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Kanwar JR, Mohan RR, Kanwar RK, et al: Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine (Lond). 5:1435–1445. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Ellington AD and Szostak JW: In vitro selection of RNA molecules that bind specific ligands. Nature. 346:818–822. 1990. View Article : Google Scholar : PubMed/NCBI
7.	Tuerk C and Gold L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 249:505–510. 1990. View Article : Google Scholar
8.	Keefe AD and Cload ST: SELEX with modified nucleotides. Curr Opin Chem Biol. 12:448–456. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Majumder P, Gomes KN and Ulrich H: Aptamers: from bench side research towards patented molecules with therapeutic applications. Expert Opin Ther Pat. 19:1603–1613. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Keefe AD, Pai S and Ellington A: Aptamers as therapeutics. Nat Rev Drug Discov. 9:537–550. 2010. View Article : Google Scholar : PubMed/NCBI
11.	Ciesiolka J and Yarus M: Small RNA-divalent domains. RNA. 2:785–793. 1996.PubMed/NCBI
12.	Hofmann HP, Limmer S, Hornung V and Sprinzl M: Ni²⁺-binding RNA motifs with an asymmetric purine-rich internal loop and a G-A base pair. RNA. 3:1289–1300. 1997.
13.	Rajendran M and Ellington AD: Selection of fluorescent aptamer beacons that light up in the presence of zinc. Anal Bioanal Chem. 390:1067–1075. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Geiger A, Burgstaller P, von der Eltz H, et al: RNA aptamers that bind L-arginine with sub-micromolar dissociation constants and high enantioselectivity. Nucleic Acids Res. 24:1029–1036. 1996. View Article : Google Scholar : PubMed/NCBI
15.	Connell GJ, Illangesekare M and Yarus M: Three small ribooligonucleotides with specific arginine sites. Biochemistry. 32:5497–5502. 1993. View Article : Google Scholar : PubMed/NCBI
16.	Mannironi C, Scerch C, Fruscoloni P and Tocchini-Valentini GP: Molecular recognition of amino acids by RNA aptamers: the evolution into an L-tyrosine binder of a dopamine-binding RNA motif. RNA. 6:520–527. 2000. View Article : Google Scholar : PubMed/NCBI
17.	Harada K and Frankel AD: Identification of two novel arginine binding DNAs. EMBO J. 14:5798–5811. 1995.PubMed/NCBI
18.	Wallis MG, Streicher B, Wank H, et al: In vitro selection of a viomycin-binding RNA pseudoknot. Chem Biol. 4:357–366. 1997. View Article : Google Scholar : PubMed/NCBI
19.	Wallace ST and Schroeder R: In vitro selection and characterization of streptomycin-binding RNAs: recognition discrimination between antibiotics. RNA. 4:112–123. 1998.PubMed/NCBI
20.	Nieuwlandt D, Wecker M and Gold L: In vitro selection of RNA ligands to substance P. Biochemistry. 34:5651–5659. 1995. View Article : Google Scholar : PubMed/NCBI
21.	Williams KP, Liu XH, Schumacher TN, et al: Bioactive and nuclease-resistant L-DNA ligand of vasopressin. Proc Natl Acad Sci USA. 94:11285–11290. 1997. View Article : Google Scholar : PubMed/NCBI
22.	Mallikaratchy P, Stahelin RV, Cao Z, et al: Selection of DNA ligands for protein kinase C-delta. Chem Commun (Camb). 30:3229–3231. 2006. View Article : Google Scholar : PubMed/NCBI
23.	Davis KA, Lin Y, Abrams B and Jayasena SD: Staining of cell surface human CD4 with 2′-F-pyrimidine-containing RNA aptamers for flow cytometry. Nucleic Acids Res. 26:3915–3924. 1998.
24.	Shangguan D, Li Y, Tang Z, et al: Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA. 103:11838–11843. 2006. View Article : Google Scholar : PubMed/NCBI
25.	Tang Z, Shangguan D, Wang K, et al: Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem. 79:4900–4907. 2007. View Article : Google Scholar : PubMed/NCBI
26.	Chen HW, Medley CD, Sefah K, et al: Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem. 3:991–1001. 2008. View Article : Google Scholar : PubMed/NCBI
27.	Sefah K, Tang ZW, Shangguan DH, et al: Molecular recognition of acute myeloid leukemia using aptamers. Leukemia. 23:235–244. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Lorger M, Engstler M, Homann M and Goringer HU: Targeting the variable surface of African trypanosomes with variant surface glycoprotein-specific, serum-stable RNA aptamers. Eukaryot Cell. 2:84–94. 2003. View Article : Google Scholar : PubMed/NCBI
29.	Tang Z, Parekh P, Turner P, et al: Generating aptamers for recognition of virus-infected cells. Clin Chem. 55:813–822. 2009. View Article : Google Scholar : PubMed/NCBI
30.	Bruno JG and Kiel JL: In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection. Biosens Bioelectron. 14:457–464. 1999. View Article : Google Scholar : PubMed/NCBI
31.	Shu D and Guo P: A viral RNA that binds ATP and contains a motif similar to an ATP-binding aptamer from SELEX. J Biol Chem. 278:7119–7125. 2003. View Article : Google Scholar : PubMed/NCBI
32.	Clark SL and Remcho VT: Aptamers as analytical reagents. Electrophoresis. 23:1335–1340. 2002. View Article : Google Scholar : PubMed/NCBI
33.	Bouvet P: Determination of nucleic acid recognition sequences by SELEX. Methods Mol Biol. 148:603–610. 2001.PubMed/NCBI
34.	Sablin EP and Fletterick RJ: Nucleotide switches in molecular motors: structural analysis of kinesins and myosins. Curr Opin Struct Biol. 11:716–724. 2001. View Article : Google Scholar : PubMed/NCBI
35.	Shenton W, Pum D, Sleytr UB and Mann S: Synthesis of cadmium sulphide superlattices using self-assembled bacterial S-layers. Nature. 389:585–587. 1997. View Article : Google Scholar
36.	Yeakley JM, Fan JB, Doucet D, et al: Profiling alternative splicing on fiber-optic arrays. Nat Biotechnol. 20:353–358. 2002. View Article : Google Scholar : PubMed/NCBI
37.	Klug SJ and Famulok M: All you wanted to know about SELEX. Mol Biol Rep. 20:97–107. 1994. View Article : Google Scholar : PubMed/NCBI
38.	Ciesiolka J, Gorski J and Yarus M: Selection of an RNA domain that binds Zn²⁺. RNA. 1:538–550. 1995.PubMed/NCBI
39.	Nimjee SM, Rusconi CP, Harrington RA and Sullenger BA: The potential of aptamers as anticoagulants. Trends Cardiovasc Med. 15:41–45. 2005. View Article : Google Scholar : PubMed/NCBI
40.	Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, et al: Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 26:442–449. 2008. View Article : Google Scholar : PubMed/NCBI
41.	Thiel KW and Giangrande PH: Therapeutic applications of DNA and RNA aptamers. Oligonucleotides. 19:209–222. 2009. View Article : Google Scholar : PubMed/NCBI
42.	Dyke CK, Steinhubl SR, Kleiman NS, et al: First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 114:2490–2497. 2006. View Article : Google Scholar
43.	Smith JE, Medley CD, Tang Z, et al: Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal Chem. 79:3075–3082. 2007. View Article : Google Scholar : PubMed/NCBI
44.	Kang WJ, Chae JR, Cho YL, et al: Multiplex imaging of single tumor cells using quantum-dot-conjugated aptamers. Small. 5:2519–2522. 2009. View Article : Google Scholar : PubMed/NCBI
45.	Zhao Z, Xu L, Shi X, et al: Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst. 134:1808–1814. 2009. View Article : Google Scholar : PubMed/NCBI
46.	Hicke BJ and Stephens AW: Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest. 106:923–928. 2000. View Article : Google Scholar : PubMed/NCBI
47.	Daniel MC and Astruc D: Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev. 104:293–346. 2004. View Article : Google Scholar
48.	Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, et al: Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science. 312:1027–1030. 2006. View Article : Google Scholar
49.	Sperling RA, Rivera Gil P, Zhang F, et al: Biological applications of gold nanoparticles. Chem Soc Rev. 37:1896–1908. 2008. View Article : Google Scholar
50.	Storhoff JJ, Lucas AD, Garimella V, et al: Homogeneous detection of unamplified genomic DNA sequences based on colorimetric scatter of gold nanoparticle probes. Nat Biotechnol. 22:883–887. 2004. View Article : Google Scholar : PubMed/NCBI
51.	Grzelczak M, Perez-Juste J, Mulvaney P and Liz-Marzan LM: Shape control in gold nanoparticle synthesis. Chem Soc Rev. 37:1783–1791. 2008. View Article : Google Scholar : PubMed/NCBI
52.	Medley CD, Smith JE, Tang Z, et al: Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells. Anal Chem. 80:1067–1072. 2008. View Article : Google Scholar : PubMed/NCBI
53.	Lu W, Arumugam SR, Senapati D, et al: Multifunctional oval-shaped gold-nanoparticle-based selective detection of breast cancer cells using simple colorimetric and highly sensitive two-photon scattering assay. ACS Nano. 4:1739–1749. 2010. View Article : Google Scholar
54.	Zhang J, Jia X, Lv XJ, et al: Fluorescent quantum dot-labeled aptamer bioprobes specifically targeting mouse liver cancer cells. Talanta. 81:505–509. 2010. View Article : Google Scholar : PubMed/NCBI
55.	Huang YF, Chang HT and Tan W: Cancer cell targeting using multiple aptamers conjugated on nanorods. Anal Chem. 80:567–572. 2008. View Article : Google Scholar : PubMed/NCBI
56.	Estevez MC, O'Donoghue MB, Chen X and Tan W: Highly fluorescent dye-doped silica nanoparticles increase flow cytometry sensitivity for cancer cell monitoring. Nano Res. 2:448–461. 2009. View Article : Google Scholar
57.	Chen X, Estevez MC, Zhu Z, et al: Using aptamer-conjugated fluorescence resonance energy transfer nanoparticles for multiplexed cancer cell monitoring. Anal Chem. 81:7009–7014. 2009. View Article : Google Scholar : PubMed/NCBI
58.	Wang L and Tan W: Multicolor FRET silica nanoparticles by single wavelength excitation. Nano Lett. 6:84–88. 2006. View Article : Google Scholar : PubMed/NCBI
59.	Wessels JT, Busse AC, Mahrt J, et al: In vivo imaging in experimental preclinical tumor research - a review. Cytometry A. 71:542–549. 2007. View Article : Google Scholar : PubMed/NCBI
60.	Shangguan D, Meng L, Cao ZC, et al: Identification of liver cancer-specific aptamers using whole live cells. Anal Chem. 80:721–728. 2008. View Article : Google Scholar : PubMed/NCBI
61.	Davis KA, Abrams B, Lin Y and Jayasena SD: Use of a high affinity DNA ligand in flow cytometry. Nucleic Acids Res. 24:702–706. 1996. View Article : Google Scholar : PubMed/NCBI
62.	Bagalkot V, Zhang L, Levy-Nissenbaum E, et al: Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 7:3065–3070. 2007. View Article : Google Scholar : PubMed/NCBI
63.	Wang AZ, Bagalkot V, Vasilliou CC, et al: Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem. 3:1311–1315. 2008. View Article : Google Scholar : PubMed/NCBI
64.	Kim D, Jeong YY and Jon S: A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano. 4:3689–3696. 2010. View Article : Google Scholar : PubMed/NCBI
65.	Bander NH: Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol. 3:216–225. 2006. View Article : Google Scholar : PubMed/NCBI
66.	Lupold SE, Hicke BJ, Lin Y and Coffey DS: Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62:4029–4033. 2002.PubMed/NCBI
67.	McNamara JO II, Andrechek ER, Wang Y, et al: Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 24:1005–1015. 2006. View Article : Google Scholar : PubMed/NCBI
68.	Ni X, Zhang Y, Ribas J, et al: Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest. 121:2383–2390. 2011. View Article : Google Scholar : PubMed/NCBI
69.	Farokhzad OC, Jon S, Khademhosseini A, et al: Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 64:7668–7672. 2004. View Article : Google Scholar : PubMed/NCBI
70.	Bleickardt E, Argiris A, Rich R, et al: Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Cancer Biol Ther. 1:646–651. 2002. View Article : Google Scholar : PubMed/NCBI
71.	Farokhzad OC, Cheng J, Teply BA, et al: Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA. 103:6315–6320. 2006. View Article : Google Scholar : PubMed/NCBI
72.	Cheng J, Teply BA, Sherifi I, et al: Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 28:869–876. 2007. View Article : Google Scholar : PubMed/NCBI
73.	Farokhzad OC, Khademhosseini A, Jon S, et al: Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal Chem. 77:5453–5459. 2005. View Article : Google Scholar : PubMed/NCBI
74.	Gu F, Zhang L, Teply BA, et al: Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA. 105:2586–2591. 2008. View Article : Google Scholar : PubMed/NCBI
75.	Dhar S, Kolishetti N, Lippard SJ and Farokhzad OC: Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA. 108:1850–1855. 2011. View Article : Google Scholar : PubMed/NCBI
76.	Ireson CR and Kelland LR: Discovery and development of anti-cancer aptamers. Mol Cancer Ther. 5:2957–2962. 2006. View Article : Google Scholar : PubMed/NCBI
77.	Soundararajan S, Chen W, Spicer EK, et al: The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 68:2358–2365. 2008. View Article : Google Scholar : PubMed/NCBI
78.	Cao Z, Tong R, Mishra A, et al: Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl. 48:6494–6498. 2009. View Article : Google Scholar : PubMed/NCBI
79.	Bates PJ, Laber DA, Miller DM, et al: Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 86:151–164. 2009. View Article : Google Scholar : PubMed/NCBI
80.	Mongelard F and Bouvet P: AS-1411, a guanosine-rich oligo-nucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther. 12:107–114. 2010.
81.	Gendler SJ: MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 6:339–353. 2001. View Article : Google Scholar : PubMed/NCBI
82.	Brockhausen I, Yang JM, Burchell J, et al: Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem. 233:607–617. 1995. View Article : Google Scholar : PubMed/NCBI
83.	Reis CA, David L, Seixas M, et al: Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer. 79:402–410. 1998. View Article : Google Scholar : PubMed/NCBI
84.	Ferreira CS, Matthews CS and Missailidis S: DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol. 27:289–301. 2006. View Article : Google Scholar : PubMed/NCBI
85.	Borbas KE, Ferreira CS, Perkins A, Bruce JI and Missailidis S: Design and synthesis of mono- and multimeric targeted radio-pharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. Bioconjug Chem. 18:1205–1212. 2007. View Article : Google Scholar
86.	Ferreira CS, Cheung MC, Missailidis S, et al: Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 37:866–876. 2009. View Article : Google Scholar : PubMed/NCBI
87.	Savla R, Taratula O, Garbuzenko O and Minko T: Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release. 153:16–22. 2011. View Article : Google Scholar : PubMed/NCBI
88.	Nolte A, Klussmann S, Bald R, et al: Mirror-design of L-oligonucleotide ligands binding to L-arginine. Nat Biotechnol. 14:1116–1119. 1996. View Article : Google Scholar : PubMed/NCBI
89.	Sayyed SG, Hagele H, Kulkarni OP, et al: Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia. 52:2445–2454. 2009. View Article : Google Scholar